Medicare Is Now Covering Wegovy and Zepbound for $50 a Month. Here's Who Actually Qualifies.

For years, the answer was the same no matter who you asked. Does Medicare cover Wegovy? No. Does Medicare cover Zepbound? No. Want a GLP-1 for weight loss on a fixed income? Pay full price, somewhere north of $1,000 a month, or don't take it at all.

That answer changed on July 1, 2026.

A new federal program called the Medicare GLP-1 Bridge is now covering some of the most talked-about medications in America for a flat $50 copay a month. Not $1,000. Not $500. Fifty dollars. And most Medicare beneficiaries either haven't heard about it, or heard a vague headline and assumed it doesn't apply to them.

For some of you, it doesn't. For a lot of you, it does. And the difference between those two groups comes down to a handful of specific details that almost nobody is explaining clearly.

Let's fix that.

What the Medicare GLP-1 Bridge Actually Is

The Bridge is a temporary CMS demonstration program running from July 1, 2026 through December 31, 2027. It exists outside the normal Part D drug benefit, which is exactly why it can do something Part D has never been legally allowed to do: pay for a weight-loss drug specifically because it's a weight-loss drug, not because it treats diabetes or heart disease.

CMS negotiated a price with the drug manufacturers well below retail. Novo Nordisk and Eli Lilly agreed to supply these medications to Medicare at roughly $245 a month, a fraction of the $1,000-plus sticker price most people are used to seeing. CMS then passes that savings on to eligible beneficiaries as a $50 monthly copay, and that copay doesn't even count against your regular Part D deductible or your annual drug spending cap. It's a separate track entirely.

That's the headline. Here's where it gets specific.

Which Drugs Are Actually Covered

The Bridge covers three medications, and only these three, in specific forms:

• Wegovy (semaglutide), both the weekly injection and the oral tablet

• Zepbound, but only the KwikPen version. The single-dose vial and the auto-injector pen are not on the covered list

• Foundayo (orforglipron), a newer oral GLP-1

Notice what's missing. Ozempic is not on that list, and it isn't a mistake. Ozempic is FDA-approved for type 2 diabetes, not weight loss, so it's already covered through your regular Part D benefit if you have diabetes. It was never going to be part of a program specifically built to close the weight-loss coverage gap, because for diabetes, that gap doesn't exist. Mounjaro faces a similar situation. If your doctor has you on it for diabetes, that's a standard Part D conversation, not a Bridge conversation.

The Eligibility Rules Nobody's Explaining Clearly

This is the part that trips people up, because qualifying for the Bridge isn't just about wanting to lose weight. CMS built specific clinical tiers, and you need to fall into one of them:

You may qualify with a BMI of 30 or higher if you also have heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or beyond.

You may also qualify with a BMI of 27 or higher if you have pre-diabetes, or a history of a prior heart attack, stroke, or peripheral artery disease.

On top of the BMI and health criteria, you have to actually be enrolled in a Medicare drug plan, either a standalone Part D plan or a Medicare Advantage plan that includes drug coverage. If you're on Original Medicare with no Part D at all, the Bridge isn't reachable until you enroll in a drug plan.

Here's something important if you've already been turned down once. A prior denial for Wegovy or Zepbound under your regular Part D coverage does not disqualify you from the Bridge. The Bridge runs on its own eligibility criteria through its own approval process. Getting a no from your Part D plan last year has nothing to do with whether you qualify for the Bridge this year.

Wait, Doesn't Medicare Already Cover Wegovy for Some People?

Yes, and this is where a lot of the confusion online comes from, because there are genuinely two separate paths to coverage running at the same time.

Since 2024, standard Part D plans have been allowed to cover Wegovy specifically for reducing cardiovascular risk in people with established heart disease and either obesity or being overweight. That's a completely separate track from the Bridge, and it runs through your normal Part D benefit, subject to your normal deductible and cost-sharing.

Zepbound has a similar side door. If you have obstructive sleep apnea and obesity, your Part D plan may cover Zepbound for that diagnosis under standard rules, again separate from the Bridge.

So depending on your specific health history, you might qualify for coverage two different ways, and one of those ways might genuinely be cheaper than the other depending on where you are in your deductible for the year. Nobody sends you a letter explaining which path is better for your situation. You have to ask, or have someone check for you.

What This Actually Costs You Once You're In

If you qualify for the Bridge, your medication is $50 for a 30-day supply, flat, regardless of which Part D benefit phase you're currently in. Your doctor still has to submit a prior authorization request along with your prescription to a central CMS processor. It isn't automatic just because you meet the BMI number. The paperwork has to go through, and the diagnosis has to be documented correctly.

If you end up covered through the standard Part D cardiovascular-risk pathway instead, your cost depends on your specific plan's formulary tier and where you are relative to your deductible and the 2026 annual out-of-pocket cap.

Either way, the days of choosing between your grocery budget and a $1,000 prescription, if you actually qualify under one of these pathways, are largely over. The problem isn't that the help doesn't exist. The problem is that almost nobody's plan, pharmacist, or mailbox is walking them through which door applies to them.

The Catch: This Doesn't Last Forever

The Bridge is explicitly temporary. It runs through the end of 2027, after which CMS intends to transition to a longer-term program called the BALANCE Model. What that permanent program will look like, and whether it keeps the same $50 copay structure, hasn't been finalized. If you qualify now, the smart move is finding out now, not waiting to see what happens in eighteen months.

How to Actually Find Out If You Qualify

Between the BMI tiers, the specific diagnoses, the drug formulations, the two separate coverage pathways, and the plan-by-plan formulary differences, this is exactly the kind of thing that's easy to get wrong reading it off a manufacturer's website and much easier to get right with someone who can pull up your actual plan and your actual prescriptions.

That's what a free Medicare plan comparison is for.

Call Health1 Medicare at 800-433-0150 and a licensed agent from our US office, a real person, not a call center, not a script, will walk through your current coverage, your prescriptions, and your health history in under 15 minutes and tell you plainly whether you qualify for the GLP-1 Bridge, whether the standard Part D pathway might actually serve you better, or whether your current plan needs a second look for reasons that have nothing to do with any of this.

No pressure. No obligation. Just fifteen minutes with someone who actually knows what they're looking at.

Call 800-433-0150 now for your free Medicare plan comparison.